Pfizer and BridgeBio Achieve Patent Victory Amid FDA Review Changes
Recent developments in the biotech sector include a patent win for Pfizer and BridgeBio, alongside changes to FDA clinical trial data review and Rocket's sale of its priority review voucher.
Editorial Staff
1 min read
Updated 10 days ago
Pfizer and BridgeBio have secured a significant patent victory, which may influence their future operations and market strategies.
In related news, the FDA is implementing changes to its clinical trial data review process, potentially affecting how new treatments are evaluated.
Additionally, Rocket Pharmaceuticals has sold its priority review voucher, a move that could have implications for its pipeline and funding.